Extracorporeal membrane oxygenation is indicated for status asthmaticus refractory to maximal conventional therapy

2013 ◽  
Vol 110 (4) ◽  
pp. 300-301 ◽  
Author(s):  
Taro Iwamoto ◽  
Kei Ikeda ◽  
Hiroshi Nakajima ◽  
Masaki Suga ◽  
Kotaro Kumano ◽  
...  
Perfusion ◽  
2016 ◽  
Vol 32 (2) ◽  
pp. 157-163 ◽  
Author(s):  
Gabriella Di Lascio ◽  
Edvin Prifti ◽  
Elmi Messai ◽  
Adriano Peris ◽  
Guy Harmelin ◽  
...  

Introduction: Status asthmaticus is a life-threatening condition characterized by progressive respiratory failure due to asthma that is unresponsive to standard therapeutic measures. We used extracorporeal membrane oxygenation (ECMO) to treat patients with near-fatal status asthamticus who did not respond to aggressive medical therapies and mechanical ventilation under controlled permissive hypercapnia. Materials and methods: Between January 2011 and October 2015, we treated 16 adult patients with status asthmaticus (8 women, 8 men, mean age: 50.5±10.6years) with veno-venous ECMO (13 patients) or veno-arterial (3 patients). Patients failed to respond to conventional therapies despite receiving the most aggressive therapies, including maximal medical treatments, mechanical ventilation under controlled permissive hypercapnia and general anesthetics. Results: Mean time spent on ECMO was 300±11.8 hours (range 36–384 hours). PaO2, PaCO2 and pH showed significant improvement promptly after ECMO initiation p=0.014, 0.001 and <0.001, respectively, and such values remained significantly improved after ECMO, p=0.004 and 0.001 and <0.001, respectively. The mean time of ventilation after decannulation until extubation was 175±145.66 hours and the median time to intensive care unit discharge after decannulation was 234±110.30 hours. All 16 patients survived without neurological sequelae. Conclusions: ECMO could provide adjunctive pulmonary support for intubated asthmatic patients who remain severely acidotic and hypercarbic despite aggressive conventional therapy. ECMO should be considered as an early treatment in patients with status asthmaticus whose gas exchange cannot be satisfactorily maintained by conventional therapy for providing adequate gas change and preventing lung injury from the ventilation.


2020 ◽  
Vol 33 (3) ◽  
pp. 404-406
Author(s):  
Chibuzo Odigwe ◽  
Jake Krieg ◽  
William Owens ◽  
Cathy Lopez ◽  
Rohan Ranjit Arya

CHEST Journal ◽  
2015 ◽  
Vol 148 (4) ◽  
pp. 323A
Author(s):  
Tejaswini Kulkarni ◽  
Krittika Teerapuncharoen ◽  
Nirmal Sharma ◽  
Keith Wille ◽  
Enrique Diaz-Guzman

2021 ◽  
Vol 24 (3) ◽  
pp. E575-E577
Author(s):  
Zairong Lin ◽  
Kun-an Huang ◽  
Dongdong Chen ◽  
Qianzhen Li

Severe bronchospasm during cardiopulmonary bypass is an unusual but potentially fatal event. No literature previously has reported such an event observed during surgery for type A aortic dissection. Herein, we report on a case of severe bronchospasm following cardiopulmonary bypass, during aortic surgery for type A aortic dissection. Bronchospasm did not respond to any conventional therapy, necessitating extracorporeal membrane oxygenation. Extracorporeal membrane oxygenation thus serves as an alternative and effective therapy for refractory bronchospasm.


2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Jan Benes ◽  
Roman Skulec ◽  
Dalibor Jilek ◽  
Ondrej Fibigr ◽  
Vladimir Cerny

AbstractRefractory status asthmaticus is the cause of rare cases of in-hospital death due to acute bronchial asthma. The most severe cases unresponsive to first, second and next line treatment may be fatal despite aggressive organ support with invasive ventilation and extracorporeal membrane oxygenation. Omalizumab, a humanized recombinant monoclonal anti-IgE antibody, is an approved add-on biological treatment for severe asthma. However, it is not indicated in an acute setting. Here, we report the case of a young patient with status asthmaticus fully dependent on extracorporeal membrane oxygenation refractory to any therapy for six days, who was successfully treated with omalizumab.


2019 ◽  
Vol 57 (3) ◽  
pp. 343-346 ◽  
Author(s):  
Lauren Greenawald ◽  
Abigail Strang ◽  
Curtis Froehlich ◽  
Aaron Chidekel

1999 ◽  
Vol 91 (6) ◽  
pp. 1577-1577 ◽  
Author(s):  
Roman Ullrich ◽  
Christine Lorber ◽  
Georg Röder ◽  
Georg Urak ◽  
Barbara Faryniak ◽  
...  

Background Recent years have seen the introduction of innovative additive therapies for acute respiratory distress syndrome. However, because there are no reliable predictors of response to a particular therapy, potential responders to a specific therapeutic intervention may be lost. Therefore, the authors evaluated the effect of a combined therapeutic approach on the survival of patients with acute respiratory distress syndrome, when treated according to a strict algorithm. Methods During a 2.5-yr period, 84 patients with acute respiratory distress syndrome were assigned to a standardized treatment protocol. Data analysis was performed by retrospective review of patient charts. Patients were treated using a stepwise treatment algorithm of pressure-controlled ventilation (peak airway pressure &lt; 35 cm H2O), positive end-expiratory pressure (PEEP; 12-15 cm H2O), permissive hypercapnia, inhaled nitric oxide (5-20 ppm), and prone positioning. These interventions were termed "conventional therapy." Response to treatment was defined as a more than 20% increase in arterial oxygen tension (PaO2). Nonresponders were triaged to extracorporeal membrane oxygenation. Results The overall survival rate was 80%. All patients received conventional therapy up to 96 h; 71 responded to conventional therapy and 59 survived (83%). Thirteen patients (15%) did not respond to conventional therapy and underwent extracorporeal membrane oxygenation; 8 of these patients (62%) survived. For the group, the mean admission lung injury score was 3.3+/-0.5, the PaO2/fractional inspired oxygen tension (F(I)O2) ratio was 96+/-45, and the Acute Physiology and Chronic Health Evaluation (APACHE) II score was 18+/-6. Conclusions The 80% overall survival rate achieved in this group of patients with severe acute respiratory distress syndrome may in part reflect the additive beneficial effects of combined treatment methods, such as airway pressure control, nitric oxide inhalation, prone position, and early triage of nonresponders to extracorporeal membrane oxygenation.


Sign in / Sign up

Export Citation Format

Share Document